The US Food and Drug Administration granted approval for daraxonrasib, a treatment developed by Revolution Medicines for pancreatic cancer. The drug, marketed under the brand name Rasonque, represents a significant advancement in addressing one of the most lethal cancer types globally.
During late-stage clinical testing involving 500 patients, those receiving the daily oral medication demonstrated median overall survival of 13.2 months, substantially higher than the 6.6-month median observed among patients undergoing standard chemotherapy treatment. The mechanism of action involves targeting the mutated KRAS gene, which is present in more than 90 percent of pancreatic tumors and drives malignant cell growth. According to the FDA, the treatment provides a “critical new option for patients facing an extraordinarily difficult and historically hard-to-treat cancer.”
Pancreatic cancer affects approximately 67,000 individuals annually in the United States and carries the highest mortality rate among major cancer types, per the American Cancer Society. The disease typically progresses rapidly, with more than half of diagnosed patients dying within three months of diagnosis, reflecting its challenging clinical trajectory and the necessity for improved therapeutic options.
The regulatory pathway for this treatment was expedited following a Breakthrough Therapy designation granted in 2025. The FDA completed its full review six months earlier than the standard timeline, with officials citing the drug’s “unprecedented results in an area of high unmet need.” Common adverse effects included rash, diarrhea, nausea, fatigue, and vomiting. Severe side effects occurred in approximately 44 percent of patients receiving daraxonrasib compared to 57.5 percent of those administered chemotherapy during the trial phase.
Notably, former US Senator Ben Sasse, who disclosed a Stage 4 pancreatic cancer diagnosis, is participating in a clinical trial of the medication and has reported tumor shrinkage following treatment.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI